Company comparison
Novo vs Novartis
In short
Novo Nordisk A/S and Novartis AG are both in Pharmaceuticals. ET&A currently rates Novo Nordisk A/S Buy and Novartis AG Accumulate. Against ET&A's Fair Value, Novo Nordisk A/S's share price currently looks better value — it sits further below what we think it is worth. Their investment styles differ (Quality/Growth/Value and Quality/Growth/Income), so they may suit different goals.
Fair Value is what ET&A estimates each company is worth today; the 12M Price Target is what we think it should be worth in about twelve months; Preferred Entry is the price range where the expected return becomes attractive enough for the risk. Expected returns are measured from the price at each valuation date. This tool shows the differences and trade-offs — it does not pick a winner. See membership
Investor View
More detail, one section at a time
Open a section to compare the reasoning and the detail.
Our view on eachOur reasoning, what could drive each higher and what could go wrong.Members
The complete ET&A view
See our full reasoning, what could drive the shares higher or go wrong, our Fair Value and Preferred Entry, and how our view has changed.
- Our View in full
- What could drive it higher / go wrong
- Fair Value & Preferred Entry
- How our view has changed
Price against valueWhere each price sits between its Preferred Entry and Fair Value.Members
Fair Value & Preferred Entry
See what ET&A thinks each company is worth, the price range where we'd be happy to buy, and whether today's price looks cheap or expensive.
Business Health, area by areaEach area's rating on ET&A's scales, side by side.
The figures behind each rating are on each company’s page.
Who each suitsInvestment style and the goals each fits.
Related ET&A research6 articles mentioning these companies.
Electricity Is Becoming the World's Most Important Industrial Advantage
29 September 2026
Markets and EconomicsThe Rate-Cutting Cycle May Be Over Before It Really Began
14 September 2026
CompaniesLululemon Shows Why Premium Brands Cannot Rely on Pricing Power Forever
7 September 2026
Markets and EconomicsChina Is Recapitalising Its Financial System. What Is Beijing Worried About?
7 September 2026
Technology & InfrastructureCritical Infrastructure Is Becoming a Battlefield
3 September 2026
Private MarketsPrivate Credit Is Starting to Show Cracks
2 September 2026
Research ViewOpen the full researchThe full researchValuation multiples and the reported financial figures, side by side.OpenClose
For detailed analysis. Each section opens on its own.
Valuation multiplesP/E, EV/EBITDA, Price/Sales and other multiples.Members
Financial figuresSize, returns and financial strength, as reported.
Values are shown in each company’s listing currency. “—” means the figure isn’t available.